Here's why they chose Abbott Laboratories (NYSE: ABT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE). To be sure, the company faces some challenges over the near term, including the negative impact of the strong U.S. dollar, healthcare staffing issues, and high inflation. In the next five years, investors can expect Moderna to have multiple data readouts for important candidates, at least one major regulatory approval, and it will start many more late-stage programs.